| TENX Stock | | | USD 7.07 0.42 6.32% |
EVP
Mr. Doug Randall is Executive Vice President Business and Commercial Operations of the Company. Prior to joining the company, Mr. Randall cofounded Phyxius Pharma, Inc. in 2011 where he served as the Chief Commercial Officer. Previously, Mr. Randall served in many senior level executive positions within the pharmaceutical industry, including Vice President of Commercial Operations at The Medicines Company Vice President of US Diabetes Marketing at SanofiAventis Pharmaceuticals and Vice President of Sales at Aventis Pharmaceuticals. Prior to the formation of Aventis Pharmaceuticals in 2000, Mr. Randall served in several senior commercial roles at the former legacy companies including Director of Respiratory Marketing, Director of Cardiovascular marketing, Director of GICNS Marketing, Director of Distribution and Pharmacy Markets, and various sales management roles since 2013.
| Tenure | 12 years |
| Address | 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 |
| Phone | (919) 855-2100 |
| Web | https://www.tenaxthera.com |
Randall started his pharmaceutical career as a sales representative for Marion Laboratories, Inc. in 1982 after earning his B.S. in Pharmacy from the University of Rhode Island.
Tenax Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.6609) % which means that it has lost $0.6609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.1379) %, meaning that it created substantial loss on money invested by shareholders. Tenax Therapeutics' management efficiency ratios could be used to measure how well Tenax Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.62 in 2025.
Return On Capital Employed is likely to rise to -1.11 in 2025. At this time, Tenax Therapeutics'
Total Assets are fairly stable compared to the past year.
Other Current Assets is likely to rise to about 2.3
M in 2025, whereas
Non Current Assets Total are likely to drop 1,220 in 2025.
Tenax Therapeutics currently holds 500.9
K in liabilities with Debt to Equity
(D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Tenax Therapeutics has a current ratio of 5.49, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Tenax Therapeutics' use of debt, we should always consider it together with its cash and equity.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. Tenax Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. Tenax Therapeutics (TENX) is traded on NASDAQ Exchange in USA. It is located in 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 and employs 5 people. Tenax Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Tenax Therapeutics Leadership Team
Elected by the shareholders, the Tenax Therapeutics' board of directors comprises two types of representatives: Tenax Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tenax. The board's role is to monitor Tenax Therapeutics' management team and ensure that shareholders' interests are well served. Tenax Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tenax Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tenax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tenax Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to
measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.